Why Reliability Is Now a Business Metric
The Startup Reckoning: Why Healthcare AI Now Demands Industry-Built Founders
0G Introduces Sealed Inference: Cryptographically Private AI Where Every Response Is Verified Inside a Hardware Enclave
TorchLight Approved as Cybersecurity Vendor Across California and Washington Education Markets
Stop watching session replays: LogRocket launches Ask Galileo, an AI-powered chat that answers any question about your users’ experience in seconds
– CFT7455 Demonstrated High Cereblon Binding Affinity and Rapid, Deep IKZF1/3 Degradation Enabling Activity across…
PC14586 selectively stabilizes the p53 Y220C mutant and restores p53 activity Robust in vivo tumor…
ZN-c3 demonstrated single agent activity, generating Exceptional Responses in a range of heavily pre-treated solid…
TH1902 anti-tumor post-treatment effect persists longer than with docetaxel alone MONTREAL, April 10, 2021 (GLOBE…
CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical…
7 objective responses observed to date in multiple tumor types New responses reported in patients…
CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) — TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage…
— Late-breaking presentation highlights preclinical data for AO-176 in T-ALL — BRISBANE, Calif., April 10,…
Preliminary data demonstrate a robust increase in HPV16+-specific T cells, including up to 8% of…
VIP236 shows enhanced tumor targeting with robust antitumor activity across multiple xenograft models First-in-human studies…
-Translational analysis of patients that do not respond to PD-(L)1 inhibitors show high pretreatment intratumoral…
Collaboration with Precision for Medicine to develop novel flow cytometry PD-1 expression assay as a…
ZUG, Switzerland and CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP),…
Inivata Presents New Data in Support of its Liquid Biopsy Technologies at AACR Virtual Annual…
– exoASO™-STAT6 mediated genetic reprogramming of tumor associated macrophages results in potent single-agent anti-tumor activity…
Pro-tumor effects detected as early as four days after Inhibigen administration Insights into Inhibigen biology…
Xerna™ TME Panel describes the tumor microenvironment based on dominant biology subtypes with prognostic capabilities…
BELTSVILLE, Md., April 10, 2021 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical…
LONDON, April 10, 2021 (GLOBE NEWSWIRE) — Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical…
SOUTH SAN FRANCISCO, Calif., April 10, 2021 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (NASDAQ: HARP),…